Curis IncNASDAQ:CRIS
- LAST PRICE4.1000
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots3.7100/ 10
- Ask / Lots4.3300/ 2
- Open / Previous Close--- / 4.1000
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CRIS |
|---|---|---|
| 09:32 ET | 571 | 3.7 |
| 09:42 ET | 553 | 3.8777 |
| 09:51 ET | 100 | 3.89 |
| 10:02 ET | 7498 | 3.83 |
| 10:08 ET | 3078 | 3.79 |
| 10:11 ET | 100 | 3.78 |
| 10:13 ET | 100 | 3.795 |
| 10:18 ET | 2413 | 3.79 |
| 10:22 ET | 756 | 3.75 |
| 10:27 ET | 141 | 3.815 |
| 10:38 ET | 100 | 3.8 |
| 10:40 ET | 100 | 3.7672 |
| 10:42 ET | 100 | 3.7675 |
| 10:47 ET | 100 | 3.76 |
| 11:16 ET | 962 | 3.805 |
| 11:21 ET | 200 | 3.8617 |
| 11:30 ET | 100 | 3.865 |
| 11:32 ET | 1300 | 3.88 |
| 11:39 ET | 175 | 3.9378 |
| 11:43 ET | 200 | 3.92 |
| 11:50 ET | 860 | 3.92 |
| 11:57 ET | 203 | 3.9479 |
| 12:03 ET | 4933 | 3.96 |
| 12:06 ET | 100 | 3.9709 |
| 12:08 ET | 1823 | 3.9197 |
| 12:14 ET | 1100 | 3.92 |
| 12:21 ET | 410 | 3.91 |
| 12:24 ET | 1000 | 3.92 |
| 12:33 ET | 1139 | 3.93 |
| 12:46 ET | 100 | 3.93 |
| 12:51 ET | 600 | 3.95 |
| 01:08 ET | 250 | 3.9756 |
| 01:09 ET | 200 | 3.9461 |
| 01:15 ET | 6999 | 4.02 |
| 01:18 ET | 5202 | 4.01 |
| 01:20 ET | 1310 | 4.05 |
| 01:24 ET | 100 | 4.03 |
| 01:31 ET | 124 | 4.0395 |
| 01:36 ET | 1224 | 4.05 |
| 01:47 ET | 100 | 4.0368 |
| 02:02 ET | 100 | 4.01 |
| 02:05 ET | 217 | 4.05 |
| 02:18 ET | 200 | 4.01 |
| 02:30 ET | 100 | 4.06 |
| 02:39 ET | 100 | 4.04 |
| 02:48 ET | 250 | 4.0235 |
| 02:56 ET | 6375 | 3.97 |
| 02:57 ET | 100 | 4 |
| 02:59 ET | 100 | 3.96 |
| 03:06 ET | 535 | 3.965 |
| 03:12 ET | 250 | 3.95 |
| 03:14 ET | 100 | 3.98 |
| 03:15 ET | 322 | 3.9792 |
| 03:17 ET | 100 | 3.945 |
| 03:26 ET | 5396 | 3.91 |
| 03:28 ET | 150 | 3.8639 |
| 03:30 ET | 200 | 3.8 |
| 03:32 ET | 100 | 3.9 |
| 03:37 ET | 100 | 3.89 |
| 03:39 ET | 500 | 3.87 |
| 03:46 ET | 100 | 3.865 |
| 03:48 ET | 100 | 3.87 |
| 03:51 ET | 100 | 3.91 |
| 03:53 ET | 1037 | 3.91 |
| 03:55 ET | 4171 | 3.99 |
| 03:57 ET | 5598 | 4.0275 |
| 04:00 ET | 2188 | 4.1 |
Nov 15, 2024
DJ Curis Price Target Maintained With a $20.00/Share by HC Wainwright & Co., from 2:37PM ET on Friday Nov 15, 2024 by Dow Jones
2:37PM ET on Friday Nov 15, 2024 by Dow Jones
Nov 14, 2024
Curis Provides Third Quarter 2024 Business Update, from 8:00AM ET on Thursday Nov 14, 2024 by Dow Jones
8:00AM ET on Thursday Nov 14, 2024 by Dow Jones*DJ Curis 3Q Loss/Shr $1.70 >CRIS, from 8:00AM ET on Thursday Nov 14, 2024 by Dow Jones
8:00AM ET on Thursday Nov 14, 2024 by Dow Jones
Nov 7, 2024
Curis to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on November 14, 2024, from 8:00AM ET on Thursday Nov 07, 2024 by Dow Jones
8:00AM ET on Thursday Nov 07, 2024 by Dow Jones
Nov 1, 2024
DJ Curis Is Maintained at Buy by HC Wainwright & Co., from 4:39PM ET on Friday Nov 01, 2024 by Dow Jones
4:39PM ET on Friday Nov 01, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Curis Inc | 34.0M | -0.5x | --- |
Affimed NV | 40.2M | -0.6x | --- |
Spruce Biosciences Inc | 20.3M | -0.5x | --- |
DURECT Corp | 26.8M | -1.6x | --- |
Tonix Pharmaceuticals Holding Corp | 38.2M | 0.0x | --- |
Collplant Biotechnologies Ltd | 47.7M | -2.7x | --- |
Company Information
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). Its other clinical programs include Fimepinostat and CA-170. Fimepinostat is an oral, dual inhibitor of histone deacetylase (HDAC), and phosphotidyl-inositol 3 kinase (PI3K) enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target V-domain Ig Suppressor of T-cell Activation (VISTA) and PDL1 immune checkpoint proteins.
Contact Information
- Headquarters
- 128 Spring Street, Building C, Suite 500LEXINGTON, MA, United States 02421
- Phone
- 617-503-6500
- Fax
- 617-503-6501
Executives
- Independent Chairman of the Board
- Martyn Greenacre
- President, Chief Executive Officer, Director
- James Dentzer
- Chief Financial Officer
- Diantha Duvall
- Chief Development Officer
- Jonathan Zung
- Independent Director
- Anne Borgman
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $34.0M |
|---|---|
Revenue (TTM) | $10.3M |
Shares Outstanding | 8.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 3.36 |
EPS | $-7.81 |
Book Value | $3.34 |
P/E Ratio | -0.5x |
Price/Sales (TTM) | 3.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -465.42% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
